Cover Image
市場調查報告書

陰道癌:開發中產品分析

Vaginal Cancer - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 360916
出版日期 內容資訊 英文 77 Pages
訂單完成後即時交付
價格
Back to Top
陰道癌:開發中產品分析 Vaginal Cancer - Pipeline Review, H1 2017
出版日期: 2017年06月13日 內容資訊: 英文 77 Pages
簡介

本報告提供陰道癌治療藥的開發情形相關調查分析,提供您開發中產品概要,參與治療藥開發的主要企業及藥物簡介,最新的開發平台趨勢等資訊。

簡介

  • 調查範圍

陰道癌概要

治療藥的開發

  • 開發中產品的概要

陰道癌:企業開發中的治療藥

陰道癌:開發中產品概況

  • 臨床階段的產品

陰道癌:企業開發中的產品

陰道癌治療藥的開發企業

  • ISA Pharmaceuticals B.V.
  • Nanotherapeutics, Inc.
  • Ono Pharmaceutical Co., Ltd.
  • Oryx GmbH & Co. KG
  • PDS Biotechnology Corporation
  • Taiwan Liposome Company, Ltd.

陰道癌:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

陰道癌:最近的開發平台趨勢

陰道癌:暫停中的計劃

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9396IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vaginal Cancer - Pipeline Review, H1 2017, provides an overview of the Vaginal Cancer (Oncology) pipeline landscape.

Vaginal cancer is a rare cancer that occurs in vagina. Symptoms includes watery vaginal discharge, a lump or mass in vagina, painful urination, constipation and pelvic pain, vaginal bleeding. Risk factors include age, Smoking, HIV infection and vaginal intraepithelial neoplasia. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Vaginal Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Vaginal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vaginal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Vaginal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Phase I stages are 5 and 1 respectively.

Vaginal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Vaginal Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Vaginal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Vaginal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Vaginal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Vaginal Cancer (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Vaginal Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Vaginal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Vaginal Cancer - Overview
    • Vaginal Cancer - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Vaginal Cancer - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Vaginal Cancer - Companies Involved in Therapeutics Development
    • ISA Pharmaceuticals BV
    • Nanotherapeutics Inc
    • Oryx GmbH & Co KG
    • PDS Biotechnology Corp
    • Taiwan Liposome Company Ltd
  • Vaginal Cancer - Drug Profiles
    • ISA-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nivolumab - Drug Profile
      • R&D Progress
    • NTO-1151 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PDS-0101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TLC-388 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vicoryx - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Vaginal Cancer - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Vaginal Cancer, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Vaginal Cancer - Pipeline by ISA Pharmaceuticals BV, H1 2017
  • Vaginal Cancer - Pipeline by Nanotherapeutics Inc, H1 2017
  • Vaginal Cancer - Pipeline by Oryx GmbH & Co KG, H1 2017
  • Vaginal Cancer - Pipeline by PDS Biotechnology Corp, H1 2017
  • Vaginal Cancer - Pipeline by Taiwan Liposome Company Ltd, H1 2017
  • Vaginal Cancer - Dormant Projects, H1 2017

List of Figures

  • Number of Products under Development for Vaginal Cancer, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top